Technology ID
TAB-4974
Innovative Thermo-Responsive Adjuvant Scaffolds for Enhanced Vaccine Delivery and Immunotherapy
E-Numbers
E-188-2015-0
Lead Inventor
Laga, Richard
Lead IC
NIAID
Co-Inventors
Lynn, Geoffrey
Seymour, Leonard
Seder, Robert
ICs
NIAID
Applications
Vaccines
Therapeutics
Therapeutic Areas
Oncology
Infectious Disease
Development Stages
Discovery
Research Products
Research Equipment
The Thermo-responsive adjuvant scaffolds (TRAS) technology offers a groundbreaking approach to vaccine delivery and immunotherapy. TRAS utilizes carriers consisting of Toll-like receptor agonists (TLRa) attached to linear polymer carriers. These carriers are designed to assemble into particles in vivo, addressing the limitations of current particle-based delivery platforms. TRAS enhances immune responses by providing the benefits of particulate delivery while avoiding issues such as scalability, heterogeneity, and stability. This technology has the potential to revolutionize vaccine development and immunotherapy for cancer treatment.
Commercial Applications
The Thermo-responsive adjuvant scaffolds (TRAS) technology has vast potential applications in vaccine development and immunotherapy. TRAS could be utilized to enhance the efficacy of a wide range of vaccines by improving the delivery of Toll-like receptor agonists (TLRa), which are potent immunostimulants. This technology could be particularly beneficial for developing vaccines against infectious diseases and cancer. Additionally, TRAS could be explored for its potential in direct immunotherapy for the treatment of cancer, leveraging its ability to enhance immune responses. The versatility and efficacy of TRAS make it a promising platform for advancing vaccine development and immunotherapy strategies.
Competitive Advantages
The Thermo-responsive adjuvant scaffolds (TRAS) technology offers several competitive advantages over existing vaccine delivery platforms. Unlike traditional particle-based platforms, TRAS is designed to exist as single molecules in solution during storage, minimizing issues related to scalability, heterogeneity, and stability. TRAS carriers assemble into particles in vivo, enhancing immune responses without the need for complex formulation processes. This innovative approach provides the benefits of particulate delivery while avoiding drawbacks associated with current technologies. Additionally, TRAS has demonstrated efficacy in murine vaccine studies, indicating its potential as a versatile platform for vaccine development and immunotherapy.
Licensing Contact: